Heparan sulphate proteoglycans fine-tune mammalian physiology

Nature

Volumn 446, Issue 7139, 2007, Pages 1030-1037

  Bishop, Joseph R ^a   Schuksz, Manuela ^a   Esko, Jeffrey D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; GENE PRODUCT; PROTEOHEPARAN SULFATE;

ENZYME; LIGAND; MUTATION; PHYSIOLOGY; POLYSACCHARIDE; PROTEIN; RODENT; SULFATE;

BASEMENT MEMBRANE; BIOSYNTHESIS; CELL MEMBRANE; CELLULAR DISTRIBUTION; EXTRACELLULAR MATRIX; HUMAN; MAMMAL; METABOLISM; MUTATION; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW;

ANIMALIA; MAMMALIA; MUS;

EID: 34247610845     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature05817     Document Type: Review

References (100)

1. Bulow, H. E. & Hobert, O. The molecular diversity of glycosaminoglycans shapes animal development. Annu. Rev. Cell Dev. Biol. 22, 375-407 (2006).
2. Hacker, U., Nybakken, K. & Perrimon, N. Heparan sulphate proteoglycans: the sweet side of development. Nature Rev. Mol. Cell Biol. 6, 530-541 (2005).
3. Haltiwanger, R. S. & Lowe, J. B. Role of glycosylation in development. Annu. Rev. Biochem. 73, 491-537 (2004).
4. Esko, J. D. & Selleck, S. B. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu. Rev. Biochem. 71, 435-471 (2002).
5. Dhoot, G. K. et al. Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science 293, 1663-1666 (2001).
6. Morimoto-Tomita, M., Uchimura, K., Werb, Z., Hemmerich, S. & Rosen, S. D. Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J. Biol. Chem. 277, 49175-49185 (2002).
7. Vlodavsky, I. et al. Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin. Cancer Biol. 12, 121-129 (2002).
8. Fedarko, N. S. & Conrad, H. E. A unique heparan sulfate in the nuclei of hepatocytes: structural changes with the growth state of the cells. J.Cell Biol. 102, 587-599 (1986).
9. Huntington, J. A. Mechanisms of glycosaminoglycan activation of the serpins in hemostasis. J. Thromb. Haemost. 1, 1535-1549 (2003).
10. Mohammadi, M., Olsen, S. K. & Ibrahimi, O. A. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 16, 107-137 (2005).
11. Forsten-Williams, K., Chua, C. C. & Nugent, M. A. The kinetics of FGF-2 binding to heparan sulfate proteoglycans and MAP kinase signaling. J. Theor. Biol. 233, 483-499 (2005).
12. Kreuger, J., Spillmann, D., Li, J. P. & Lindahl, U. Interactions between heparan sulfate and proteins: the concept of specificity. J. Cell Biol. 174, 323-327 (2006).
13. Alexopoulou, A. N., Multhaupt, H. A. & Couchman, J. R. Syndecans in wound healing, inflammation and vascular biology. Int. J. Biochem. Cell Biol. 39, 505-528 (2006).
14. Couchman, J. R., Chen, L. G. & Woods, A. Syndecans and cell adhesion. Int. Rev. Cytol. 207, 113-150 (2001).
15. Kirkpatrick, C. A. et al. The function of a Drosophila glypican does not depend entirely on heparan sulfate modification. Dev. Biol. 300, 570-582 (2006).
16. Reizes, O. et al. Transgenic expression of syndecan-1 uncovers a physiological control of feeding behavior by syndecan-3. Cell 106, 105-116 (2001).
17. Strader, A. D., Reizes, O., Woods, S. C., Benoit, S. C. & Seeley, R. J. Mice lacking the syndecan-3 gene are resistant to diet-induced obesity. J. Clin. Invest. 114, 1354-1360 (2004).
18. Zcharia, E. et al. Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J. 18, 252-263 (2004).
19. Mahley, R. W. & Ji, Z. S. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J. Lipid Res. 40, 1-16 (1999).
20. MacArthur, J. M. et al. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J. Clin. Invest. 117, 153-164 (2007).
21. Fuki, I. V. et al. The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. J. Clin. Invest. 100, 1611-1622 (1997).
22. Zeng, B. J., Mortimer, B. C., Martins, I. J., Seydel, U. & Redgrave, T. G. Chylomicron remnant uptake is regulated by the expression and function of heparan sulfate proteoglycan in hepatocytes. J. Lipid Res. 39, 845-860 (1998).
23. Iozzo, R. V. Basement membrane proteoglycans: from cellar to ceiling. Nature Rev. Mol. Cell Biol. 6, 646-656 (2005).
24. Raats, C. J. I., Van den Born, J. & Berden, J. H. M. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int. 57, 385-400 (2000).
25. Kanwar, Y. S., Linker, A. & Farquhar, M. G. Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J. Cell Biol. 86, 688-693 (1980).
26. Groffen, A. J. et al. Agrin is a major heparan sulfate proteoglycan in the human glomerular basement membrane. J. Histochem. Cytochem. 46, 19-27 (1998).
27. Arikawa-Hirasawa, E., Watanabe, H., Takami, H., Hassell, J. R. & Yamada, Y. Perlecan is essential for cartilage and cephalic development. Nature Genet. 23, 354-358 (1999).
28. Rossi, M. et al. Heparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney. EMBO J. 22, 236-245 (2003).
29. Morita, H. et al. Heparan sulfate of perlecan is involved in glomerular filtration. J. Am. Soc. Nephrol. 16, 1703-1710 (2005).
30. Utriainen, A. et al. Structurally altered basement membranes and hydrocephalus in a type XVIII collagen deficient mouse line. Hum. Mol. Genet. 13, 2089-2099 (2004).
31. Gautam, M. et al. Defective neuromuscular synaptogenesis in agrin-deficient mutant mice. Cell 85, 525-535 (1996).
32. Westphal, V. et al. Reduced heparan sulfate accumulation in enterocytes contributes to protein-losing enteropathy in a congenital disorder of glycosylation. Am. J. Pathol. 157, 1917-1925 (2000).
33. Bode, L., Eklund, E. A., Murch, S. & Freeze, H. H. Heparan sulfate depletion amplifies TNF-α-induced protein leakage in an in vitro model of protein-losing enteropathy. Am. J. Physiol. Gastrointest. Liver Physiol. 288, G1015-G1023 (2005).
34. Donnelly, J. P., Rosenthal, A., Castle, V. P. & Holmes, R. D. Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation. J. Pediatr. 130, 474-478 (1997).
35. Kronenberg, H. M. Developmental regulation of the growth plate. Nature 423, 332-336 (2003).
36. Koziel, L., Kunath, M., Kelly, O. G. & Vortkamp, A. Ext1-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification. Dev. Cell 6, 801-813 (2004).
37. Lander, A. D., Nie, Q. & Wan, F. Y. Do morphogen gradients arise by diffusion? Dev. Cell 2, 785-796 (2002).
38. Arikawa-Hirasawa, E. et al. Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene. Nature Genet. 27, 431-434 (2001).
39. Stickens, D., Zak, B. M., Rougier, N., Esko, J. D. & Werb, Z. Mice deficient in Ext2 lack heparan sulfate and develop exostoses. Development 132, 5055-5068 (2005).
40. Hovey, R. C., Trott, J. F. & Vonderhaar, B. K. Establishing a framework for the functional mammary gland: from endocrinology to morphology. J. Mammary Gland Biol. Neoplasia 7, 17-38 (2002).
41. Liu, B. Y., McDermott, S. P., Khwaja, S. S. & Alexander, C. M. The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc. Natl Acad. Sci. USA 101, 4158-4163 (2004).
42. Gautam, M., DeChiara, T. M., Glass, D. J., Yancopoulos, G. D. & Sanes, J. R. Distinct phenotypes of mutant mice lacking agrin, MuSK, or rapsyn. Brain Res. Dev. Brain Res. 114, 171-178 (1999).
43. Jenniskens, G. J. et al. Phenotypic knockout of heparan sulfates in myotubes impairs excitation-induced calcium spiking. FASEB J. 17, NIL606-NIL629 (2003).
44. Mook-Jung, I. & Gordon, H. Acetylcholine receptor clustering in C2 muscle cells requires chondroitin sulfate. J.Neurobiol. 28, 482-492 (1995).
45. McDonnell, K. M. & Grow, W. A. Reduced glycosaminoglycan sulfation diminishes the agrin signal transduction pathway. Dev. Neurosci. 26, 1-10 (2004).
46. Kramer, K. L. & Yost, H. J. Ectodermal syndecan-2 mediates left-right axis formation in migrating mesoderm as a cell-nonautonomous Vg1 cofactor. Dev. Cell 2, 115-124(2002).
47. Jakobsson, L. et al. Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis. Dev. Cell 10, 625-634 (2006).
48. Parish, C. R. The role of heparan sulphate in inflammation. Nature Rev. Immunol. 6, 633-643 (2006).
49. Wang, L., Fuster, M., Sriramarao, P. & Esko, J. D. Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nature Immunol. 6, 902-910 (2005).
50. Abrink, M., Grujic, M. & Pejler, G. Serglycin is essential for maturation of mast cell secretory granule. J. Biol. Chem. 279, 40897-40905 (2004).
51. Humphries, D. E. et al. Heparin is essential for the storage of specific granule proteases in mast cells. Nature 400, 769-772 (1999).
52. Forsberg, E. et al. Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme. Nature 400, 773-776 (1999).
53. Grujic, M. et al. Serglycin-deficient cytotoxic T lymphocytes display defective secretory granule maturation and granzyme B storage. J. Biol. Chem. 280, 33411-33418 (2005).
54. Zernichow, L. et al. Serglycin is the major secreted proteoglycan in macrophages and has a role in the regulation of macrophage tumor necrosis factor-α secretion in response to lipopolysaccharide. J. Biol. Chem. 281, 26792-26801 (2006).
55. Sher, I. et al. Targeting perlecan in human keratinocytes reveals novel roles for perlecan in epidermal formation. J. Biol. Chem. 281, 5178-5187 (2006).
56. Zhou, Z. et al. Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice. Cancer Res. 64, 4699-4702 (2004).
57. Echtermeyer, F. et al. Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J. Clin. Invest. 107, 9-14 (2001).
58. Stepp, M. A. et al. Defects in keratinocyte activation during wound healing in the syndecan-1-deficient mouse. J. Cell Sci. 115, 4517-4531 (2002).
59. Kainulainen, V., Wang, H. M., Schick, C. & Bernfield, M. Syndecans, heparan sulfate proteoglycans, maintain the proteolytic balance of acute wound fluids. J. Biol. Chem. 273, 11563-11569 (1998).
60. Midwood, K. S., Valenick, L. V., Hsia, H. C. & Schwarzbauer, J. E. Coregulation of fibronectin signaling and matrix contraction by tenascin-C and syndecan-4. Mol. Biol. Cell 15, 5670-5677 (2004).
61. Cool, S. M. & Nurcombe, V. Heparan sulfate regulation of progenitor cell fate. J. Cell Biochem. 99, 1040-1051 (2006).
62. Cornelison, D. D. et al. Essential and separable roles for syndecan-3 and syndecan-4 in skeletal muscle development and regeneration. Genes Dev. 18, 2231-2236 (2004).
63. Zcharia, E. et al. Heparanase regulates murine hair growth. Am. J. Pathol. 166, 999-1008 (2005).
64. De Agostini, A., Watkins, S. C., Slayter, H. S., Youssoufian, H. & Rosenberg, R. D. Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. J. Cell Biol. 111, 1293-1304 (1990).
65. Marcum, J. A., Fritze, L., Galli, S. J., Karp, G. & Rosenberg, R. D. Microvascular heparin-like species with anticoagulant activity. Am. J. Physiol. 245, H725-H733 (1983).
66. HajMohammadi, S. et al. Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis. J. Clin. Invest. 111, 989-999 (2003).
67. Shworak, N. W., HajMohammadi, S., De Agostini, A. I. & Rosenberg, R. D. Mice deficient in heparan sulfate 3-O-sulfotransferase-1: normal hemostasis with unexpected perinatal phenotypes. Glycoconj. J. 19, 355-361 (2002).
68. Hasan, S. et al. Coordinate expression of anticoagulant heparan sulfate proteoglycans and serine protease inhibitors in the rat ovary: a potent system of proteolysis control. Biol. Reprod. 66, 144-158 (2002).
69. Hosseini, G., Liu, J. & De Agostini, A. I. Characterization and hormonal modulation of anticoagulant heparan sulfate proteoglycans synthesized by rat ovarian granulosa cells. J. Biol. Chem. 271, 22090-22099 (1996).
70. Fuster, M. M. & Esko, J. D. The sweet and sour of cancer: glycans as novel therapeutic targets. Nature Rev. Cancer 5, 526-542 (2005).
71. van Horssen, J., Wesseling, P., van den Heuvel, L. P., de Waal, R. M. & Verbeek, M. M. Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurol. 2, 482-492 (2003).
72. Li, J. P. et al. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc. Natl Acad. Sci. USA 102, 6473-6477 (2005).
73. Li, Q., Park, P. W., Wilson, C. L. & Parks, W. C. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111, 635-646 (2002).
74. Park, P. W., Pier, G. B., Hinkes, M. T. & Bernfield, M. Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence. Nature 411, 98-102 (2001).
75. Haynes, A. et al. Syndecan 1 shedding contributes to Pseudomonas aeruginosa sepsis. Infect. Immun. 73, 7914-7921 (2005).
76. Xu, J., Park, P. W., Kheradmand, F. & Corry, D. B. Endogenous attenuation of allergic lung inflammation by syndecan-1. J. Immunol. 174, 5758-5765 (2005).
77. Dinglasan, R. R. & Jacobs-Lorena, M. Insight into a conserved lifestyle: protein-carbohydrate adhesion strategies of vector-borne pathogens. Infect. Immun. 73, 7797-7807 (2005).
78. Bishop, J. R. & Esko, J. D. The elusive role of heparan sulfate in Toxoplasma gondii infection. Mol. Biochem. Parasitol. 139, 267-269 (2005).
79. Bishop, J. R., Crawford, B. E. & Esko, J. D. Cell surface heparan sulfate promotes replication of Toxoplasma gondii. Infect. Immun. 73, 5395-5401 (2005).
80. Cano-Gauci, D. F. et al. Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome. J. Cell Biol. 146, 255-264 (1999).
81. Chiao, E. et al. Overgrowth of a mouse model of the Simpson-Golabi-Behmel syndrome is independent of IGF signaling. Dev. Biol. 243, 185-206 (2002).
82. Kaksonen, M. et al. Syndecan-3-deficient mice exhibit enhanced LTP and impaired hippocampus-dependent memory. Mol. Cell. Neurosci. 21, 158-172 (2002).
83. Grobe, K. et al. Cerebral hypoplasia and craniofacial defects in mice lacking heparan sulfate Ndst1 gene function. Development 132, 3777-3786 (2005).
84. Ringvall, M. et al. Defective heparan sulfate biosynthesis and neonatal lethality in mice lacking N-deacetylase/N- sulfotransferase-1. J. Biol. Chem. 275, 25926-25930 (2000).
85. Pan, Y., Woodbury, A., Esko, J. D., Grobe, K. & Zhang, X. Heparan sulfate biosynthetic gene Ndst1 is required for FGF signaling in early lens development. Development 133, 4933-4944 (2006).
86. Bullock, S. L., Fletcher, J. M., Beddington, R. S. & Wilson, V. A. Renal agenesis in mice homozygous for a gene trap mutation in the gene encoding heparan sulfate 2-sulfotransferase. Genes Dev. 12, 1894-1906 (1998).
87. Li, J. P. et al. Targeted disruption of a murine glucuronyl C5-epimerase gene results in heparan sulfate lacking L-iduronic acid and in neonatal lethality. J. Biol. Chem. 278, 28363-28366 (2003).
88. Serpinskaya, A. S., Feng, G., Sanes, J. R. & Craig, A. M. Synapse formation by hippocampal neurons from agrin-deficient mice. Dev. Biol. 205, 65-78 (1999).
89. Arikawa-Hirasawa, E., Rossi, S. G., Rotundo, R. L. & Yamada, Y. Absence of acetylcholinesterase at the neuromuscular junctions of perlecan-null mice. Nature Neurosci. 5, 119-123 (2002).
90. Viviano, B. L. et al. Altered hematopoiesis in glypican-3-deficient mice results in decreased osteoclast differentiation and a delay in endochondral ossification. Dev. Biol. 282, 152-162 (2005).
91. Paine-Saunders, S., Viviano, B. L., Zupicich, J., Skarnes, W. C. & Saunders, S. glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development. Dev. Biol. 225, 179-187 (2000).
92. Pallerla, S. R., Pan, Y., Zhang, X., Esko, J. D. & Grobe, K. Heparan sulfate Ndst1 gene function variably regulates multiple signaling pathways during mouse development. Dev. Dyn. 236, 556-563 (2007).
93. Kram, V. et al. Heparanase is expressed in osteoblastic cells and stimulates bone formation and bone mass. J. Cell Physiol. 207, 784-792 (2006).
94. Zcharia, E. et al. Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J. 19, 211-221 (2005).
95. Li, Q. & Olsen, B. R. Increased angiogenic response in aortic explants of collagen XVIII/endostatin-null mice. Am. J. Pathol. 165, 415-424 (2004).
96. Moulton, K. S. et al. Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis. Circulation 110, 1330-1336 (2004).
97. Gotte, M. et al. Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature. Invest. Ophthalmol. Vis. Sci. 43, 1135-1141 (2002).
98. Ishiguro, K. et al. Syndecan-4 deficiency impairs the fetal vessels in the placental labyrinth. Dev. Dyn. 219, 539-544 (2000).
99. Fan, G. et al. Targeted disruption of NDST-1 gene leads to pulmonary hypoplasia and neonatal respiratory distress in mice. FEBS Lett. 467, 7-11 (2000).
100. Ishiguro, K. et al. Syndecan-4 deficiency increases susceptibility to κ-carrageenan-induced renal damage. Lab. Invest. 81, 509-516 (2001).